PDF herunterladen
Semin Liver Dis 2022; 42(01): 034-047
DOI: 10.1055/s-0041-1739455
Review Article

The Neglected Role of Bile Duct Epithelial Cells in NASH

Massimiliano Cadamuro
1   Department of Molecular Medicine (DMM), University of Padua, Padua, Italy
,
Alberto Lasagni
2   Division of General Medicine, Padua University-Hospital, Padua, Italy
,
Samantha Sarcognato
3   Department of Pathology, Azienda ULSS2 Marca Trevigiana, Treviso, Italy
,
Maria Guido
3   Department of Pathology, Azienda ULSS2 Marca Trevigiana, Treviso, Italy
4   Department of Medicine (DIMED), University of Padua, Padua, Italy
,
Roberto Fabris
5   Division of Clinica Medica 3, Center for the Study and the Integrated Management of Obesity, Padua University-Hospital, Padua, Italy
,
Mario Strazzabosco
6   Department of Internal Medicine, Digestive Disease Section, Liver Center, Yale University, New Haven, Connecticut
,
Alastair J. Strain
7   School of Biosciences, University of Birmingham, Birmingham, United Kingdom
,
Paolo Simioni
2   Division of General Medicine, Padua University-Hospital, Padua, Italy
4   Department of Medicine (DIMED), University of Padua, Padua, Italy
,
Erica Villa
8   Gastroenterology Unit, Department of Medical Specialties, University of Modena & Reggio Emilia and Modena University-Hospital, Modena, Italy
,
Luca Fabris
1   Department of Molecular Medicine (DMM), University of Padua, Padua, Italy
2   Division of General Medicine, Padua University-Hospital, Padua, Italy
6   Department of Internal Medicine, Digestive Disease Section, Liver Center, Yale University, New Haven, Connecticut
› Institutsangaben
› Weitere Informationen
    Lizenzen und Reprints

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and affects 25% of the population in Western countries. NAFLD is the hepatic manifestation of the metabolic syndrome, linked to insulin resistance, which is the common pathogenetic mechanism. In approximately 40% of NAFLD patients, steatosis is associated with necro-inflammation and fibrosis, resulting in nonalcoholic steatohepatitis (NASH), a severe condition that may progress to cirrhosis and liver cancer. Although the hepatocyte represents the main target of the disease, involvement of the bile ducts occurs in a subset of patients with NASH, and is characterized by ductular reaction and activation of the progenitor cell compartment, which incites portal fibrosis and disease progression. We aim to dissect the multiple biological effects that adipokines and metabolic alterations exert on cholangiocytes to derive novel information on the mechanisms driven by insulin resistance, which promote fibro-inflammation and carcinogenesis in NASH.

Keywords

nonalcoholic fatty liver disease - insulin resistance - metabolic syndrome - ductular reaction - cholangiocarcinoma


Publikationsverlauf

Artikel online veröffentlicht:
18. November 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Younossi ZM. Non-alcoholic fatty liver disease—a global public health perspective. J Hepatol 2019; 70 (03) 531-544
    CrossrefPubMedGoogle Scholar
  • 2 Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol 2019; 16 (07) 411-428
    Google Scholar
  • 3 Chalasani N, Younossi Z, Lavine JE. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67 (01) 328-357
    CrossrefPubMedGoogle Scholar
  • 4 Sanyal AJ, Brunt EM, Kleiner DE. et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54 (01) 344-353
    CrossrefPubMedGoogle Scholar
  • 5 Tilg H, Effenberger M. From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol 2020; 17 (07) 387-388
    CrossrefPubMedGoogle Scholar
  • 6 Egger G, Dixon J. Beyond obesity and lifestyle: a review of 21st century chronic disease determinants. BioMed Res Int 2014; 2014: 731685
    CrossrefPubMedGoogle Scholar
  • 7 Wang F, Zhang L, Zhang Y. et al. Meta-analysis on night shift work and risk of metabolic syndrome. Obes Rev 2014; 15 (09) 709-720
    CrossrefPubMedGoogle Scholar
  • 8 Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM 2007; 100 (07) 395-404
    CrossrefPubMedGoogle Scholar
  • 9 Angulo P, Machado MV, Diehl AM. Fibrosis in nonalcoholic fatty liver disease: mechanisms and clinical implications. Semin Liver Dis 2015; 35 (02) 132-145
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 10 Ekstedt M, Hagström H, Nasr P. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61 (05) 1547-1554
    CrossrefPubMedGoogle Scholar
  • 11 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64 (01) 73-84
    CrossrefPubMedGoogle Scholar
  • 12 Hagström H, Nasr P, Ekstedt M. et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 2017; 67 (06) 1265-1273
    CrossrefPubMedGoogle Scholar
  • 13 Adams LA, Lymp JF, St Sauver J. et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129 (01) 113-121
    CrossrefPubMedGoogle Scholar
  • 14 Stine JG, Wentworth BJ, Zimmet A. et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 2018; 48 (07) 696-703
    CrossrefPubMedGoogle Scholar
  • 15 Wongjarupong N, Assavapongpaiboon B, Susantitaphong P. et al. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis. BMC Gastroenterol 2017; 17 (01) 149
    CrossrefPubMedGoogle Scholar
  • 16 Moeini A, Sia D, Zhang Z. et al. Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol 2017; 66 (05) 952-961
    CrossrefPubMedGoogle Scholar
  • 17 Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020; 17 (03) 139-152
    CrossrefPubMedGoogle Scholar
  • 18 Schuppan D, Surabattula R, Wang XY. Determinants of fibrosis progression and regression in NASH. J Hepatol 2018; 68 (02) 238-250
    CrossrefPubMedGoogle Scholar
  • 19 Ahima RS. Insulin resistance: cause or consequence of nonalcoholic steatohepatitis?. Gastroenterology 2007; 132 (01) 444-446
    CrossrefPubMedGoogle Scholar
  • 20 Siddle K, Hales CN. Hormonal control of adipose tissue lipolysis. Proc Nutr Soc 1975; 34 (03) 233-239
    CrossrefPubMedGoogle Scholar
  • 21 Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106 (02) 171-176
    CrossrefPubMedGoogle Scholar
  • 22 Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9 (05) 367-377
    CrossrefPubMedGoogle Scholar
  • 23 Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism 2016; 65 (08) 1049-1061
    CrossrefPubMedGoogle Scholar
  • 24 Kasumov T, Li L, Li M. et al. Ceramide as a mediator of non-alcoholic fatty liver disease and associated atherosclerosis. PLoS One 2015; 10 (05) e0126910
    CrossrefPubMedGoogle Scholar
  • 25 Hirsova P, Ibrabim SH, Gores GJ, Malhi H. Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. J Lipid Res 2016; 57 (10) 1758-1770
    CrossrefPubMedGoogle Scholar
  • 26 Zisser A, Ipsen DH, Tveden-Nyborg P. Hepatic stellate cell activation and inactivation in NASH-fibrosis-roles as putative treatment targets?. Biomedicines 2021; 9 (04) 365
    CrossrefPubMedGoogle Scholar
  • 27 Zhang C, Klett EL, Coleman RA. Lipid signals and insulin resistance. Clin Lipidol 2013; 8 (06) 659-667
    CrossrefPubMedGoogle Scholar
  • 28 Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat?. J Hepatol 2006; 44 (02) 253-261
    CrossrefPubMedGoogle Scholar
  • 29 Johnston AM, Pirola L, Van Obberghen E. Molecular mechanisms of insulin receptor substrate protein-mediated modulation of insulin signalling. FEBS Lett 2003; 546 (01) 32-36
    CrossrefPubMedGoogle Scholar
  • 30 Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454 (7203): 428-435
    CrossrefPubMedGoogle Scholar
  • 31 Giovannucci E, Harlan DM, Archer MC. et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33 (07) 1674-1685
    CrossrefPubMedGoogle Scholar
  • 32 Yokomuro S, Tsuji H, Lunz III JG. et al. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology 2000; 32 (01) 26-35
    CrossrefPubMedGoogle Scholar
  • 33 Locatelli L, Cadamuro M, Spirlì C. et al. Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis. Hepatology 2016; 63 (03) 965-982
    CrossrefPubMedGoogle Scholar
  • 34 Bril F, Lomonaco R, Orsak B. et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology 2014; 59 (06) 2178-2187
    CrossrefPubMedGoogle Scholar
  • 35 Lesage GD, Marucci L, Alvaro D. et al. Insulin inhibits secretin-induced ductal secretion by activation of PKC alpha and inhibition of PKA activity. Hepatology 2002; 36 (03) 641-651
    CrossrefPubMedGoogle Scholar
  • 36 Cusi K, Maezono K, Osman A. et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000; 105 (03) 311-320
    CrossrefPubMedGoogle Scholar
  • 37 Zhang J, Zhao Y, Xu C. et al. Association between serum free fatty acid levels and nonalcoholic fatty liver disease: a cross-sectional study. Sci Rep 2014; 4: 5832
    CrossrefPubMedGoogle Scholar
  • 38 Natarajan SK, Ingham SA, Mohr AM. et al. Saturated free fatty acids induce cholangiocyte lipoapoptosis. Hepatology 2014; 60 (06) 1942-1956
    CrossrefPubMedGoogle Scholar
  • 39 Natarajan SK, Stringham BA, Mohr AM. et al. FoxO3 increases miR-34a to cause palmitate-induced cholangiocyte lipoapoptosis. J Lipid Res 2017; 58 (05) 866-875
    CrossrefPubMedGoogle Scholar
  • 40 Martínez AK, Glaser SS. Cholangiocyte lipoapoptosis: implications for biliary damage during nonalcoholic fatty liver disease. Hepatology 2014; 60 (06) 1809-1811
    CrossrefPubMedGoogle Scholar
  • 41 Kennedy L, Meadows V, Sybenga A. et al. Mast cells promote nonalcoholic fatty liver disease phenotypes and microvesicular steatosis in mice fed a Western diet. Hepatology 2021; 74 (01) 164-182
    CrossrefPubMedGoogle Scholar
  • 42 Lewitt MS, Dent MS, Hall K. The insulin-like growth factor system in obesity, insulin resistance and type 2 diabetes mellitus. J Clin Med 2014; 3 (04) 1561-1574
    CrossrefPubMedGoogle Scholar
  • 43 Sedlaczek N, Hasilik A, Neuhaus P, Schuppan D, Herbst H. Focal overexpression of insulin-like growth factor 2 by hepatocytes and cholangiocytes in viral liver cirrhosis. Br J Cancer 2003; 88 (05) 733-739
    CrossrefPubMedGoogle Scholar
  • 44 Friedrich N, Thuesen B, Jørgensen T. et al. The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care 2012; 35 (04) 768-773
    CrossrefPubMedGoogle Scholar
  • 45 Dichtel LE, Corey KE, Misdraji J. et al. The association between IGF-1 levels and the histologic severity of nonalcoholic fatty liver disease. Clin Transl Gastroenterol 2017; 8 (01) e217
    CrossrefPubMedGoogle Scholar
  • 46 Cousin SP, Hügl SR, Wrede CE, Kajio H, Myers Jr MG, Rhodes CJ. Free fatty acid-induced inhibition of glucose and insulin-like growth factor I-induced deoxyribonucleic acid synthesis in the pancreatic beta-cell line INS-1. Endocrinology 2001; 142 (01) 229-240
    CrossrefPubMedGoogle Scholar
  • 47 Alisi A, Pampanini V, De Stefanis C. et al. Expression of insulin-like growth factor I and its receptor in the liver of children with biopsy-proven NAFLD. PLoS One 2018; 13 (07) e0201566
    CrossrefPubMedGoogle Scholar
  • 48 Weroha SJ, Haluska P. The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am 2012; 41 (02) 335-350 , vi
    CrossrefPubMedGoogle Scholar
  • 49 Alvaro D, Barbaro B, Franchitto A. et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol 2006; 169 (03) 877-888
    CrossrefPubMedGoogle Scholar
  • 50 Saengboonmee C, Seubwai W, Lert-Itthiporn W, Sanlung T, Wongkham S. Association of diabetes mellitus and cholangiocarcinoma: update of evidence and the effects of antidiabetic medication. Can J Diabetes 2021; 45 (03) 282-290
    CrossrefPubMedGoogle Scholar
  • 51 Marzioni M, Alpini G, Saccomanno S. et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology 2007; 133 (01) 244-255
    CrossrefPubMedGoogle Scholar
  • 52 Chen BD, Zhao WC, Dong JD, Sima H. Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues. Mol Biol Rep 2014; 41 (07) 4313-4320
    CrossrefPubMedGoogle Scholar
  • 53 Chen L, Wu N, Kennedy L. et al. Inhibition of secretin/secretin receptor axis ameliorates non-alcoholic fatty liver disease phenotypes. Hepatology 2021; In press
    PubMedGoogle Scholar
  • 54 El Husseny MWA, Mamdouh M, Shaban S. et al. Adipokines: potential therapeutic targets for vascular dysfunction in type II diabetes mellitus and obesity. J Diabetes Res 2017; 2017: 8095926
    CrossrefPubMedGoogle Scholar
  • 55 Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007; 92 (03) 1023-1033
    CrossrefPubMedGoogle Scholar
  • 56 Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003; 278 (46) 45777-45784
    CrossrefPubMedGoogle Scholar
  • 57 Ghadge AA, Khaire AA, Kuvalekar AA. Adiponectin: a potential therapeutic target for metabolic syndrome. Cytokine Growth Factor Rev 2018; 39: 151-158
    CrossrefPubMedGoogle Scholar
  • 58 Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 2004; 40 (01) 46-54
    CrossrefPubMedGoogle Scholar
  • 59 Bugianesi E, Pagotto U, Manini R. et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005; 90 (06) 3498-3504
    CrossrefPubMedGoogle Scholar
  • 60 Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60 (03) 313-326
    CrossrefPubMedGoogle Scholar
  • 61 Moschen AR, Molnar C, Wolf AM. et al. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol 2009; 51 (04) 765-777
    CrossrefPubMedGoogle Scholar
  • 62 La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol 2004; 4 (05) 371-379
    CrossrefPubMedGoogle Scholar
  • 63 Ikejima K, Okumura K, Kon K, Takei Y, Sato N. Role of adipocytokines in hepatic fibrogenesis. J Gastroenterol Hepatol 2007; 22 (Suppl. 01) S87-S92
    CrossrefPubMedGoogle Scholar
  • 64 Shen J, Sakaida I, Uchida K, Terai S, Okita K. Leptin enhances TNF-alpha production via p38 and JNK MAPK in LPS-stimulated Kupffer cells. Life Sci 2005; 77 (13) 1502-1515
    CrossrefPubMedGoogle Scholar
  • 65 Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism 2016; 65 (08) 1062-1079
    CrossrefPubMedGoogle Scholar
  • 66 Izzo P, Izzo S, DI Cello P. et al. Role of leptin in neoplastic and biliary tree disease. In Vivo 2020; 34 (05) 2485-2490
    CrossrefPubMedGoogle Scholar
  • 67 Fava G, Alpini G, Rychlicki C. et al. Leptin enhances cholangiocarcinoma cell growth. Cancer Res 2008; 68 (16) 6752-6761
    CrossrefPubMedGoogle Scholar
  • 68 Yan C, Yang Q, Shen HM, Spitsbergen JM, Gong Z. Chronically high level of tgfb1a induction causes both hepatocellular carcinoma and cholangiocarcinoma via a dominant Erk pathway in zebrafish. Oncotarget 2017; 8 (44) 77096-77109
    CrossrefPubMedGoogle Scholar
  • 69 Peng C, Sun Z, Li O. et al. Leptin stimulates the epithelial–mesenchymal transition and pro–angiogenic capability of cholangiocarcinoma cells through the miR–122/PKM2 axis. Int J Oncol 2019; 55 (01) 298-308
    PubMedGoogle Scholar
  • 70 Kennedy L, Hargrove L, Demieville J. et al. Knockout of l-histidine decarboxylase prevents cholangiocyte damage and hepatic fibrosis in mice subjected to high-fat diet feeding via disrupted histamine/leptin signaling. Am J Pathol 2018; 188 (03) 600-615
    CrossrefPubMedGoogle Scholar
  • 71 Sorrentino P, Tarantino G, Perrella A, Micheli P, Perrella O, Conca P. A clinical-morphological study on cholestatic presentation of nonalcoholic fatty liver disease. Dig Dis Sci 2005; 50 (06) 1130-1135
    CrossrefPubMedGoogle Scholar
  • 72 Híndi M, Levy C, Couto CA, Bejarano P, Mendes F. Primary biliary cirrhosis is more severe in overweight patients. J Clin Gastroenterol 2013; 47 (03) e28-e32
    CrossrefPubMedGoogle Scholar
  • 73 Berzigotti A, Garcia-Tsao G, Bosch J. et al; Portal Hypertension Collaborative Group. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 2011; 54 (02) 555-561
    CrossrefPubMedGoogle Scholar
  • 74 Kinoshita M, Kubo S, Tanaka S. et al. The association between non-alcoholic steatohepatitis and intrahepatic cholangiocarcinoma: a hospital based case-control study. J Surg Oncol 2016; 113 (07) 779-783
    CrossrefPubMedGoogle Scholar
  • 75 Wang Y, Kory N, BasuRay S, Cohen JC, Hobbs HH. PNPLA3, CGI-58, and inhibition of hepatic triglyceride hydrolysis in mice. Hepatology 2019; 69 (06) 2427-2441
    CrossrefPubMedGoogle Scholar
  • 76 Romeo S, Kozlitina J, Xing C. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40 (12) 1461-1465
    CrossrefPubMedGoogle Scholar
  • 77 Valenti L, Al-Serri A, Daly AK. et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51 (04) 1209-1217
    CrossrefPubMedGoogle Scholar
  • 78 Ruiz JN, Kröner PT, Wijarnpreecha K, Corral JE, Harnois DM, Lukens FJ. Increased odds of cholangiocarcinoma in Hispanics: results of a nationwide analysis. Eur J Gastroenterol Hepatol 2020; 32 (01) 116-119
    CrossrefPubMedGoogle Scholar
  • 79 Hassan MM, Kaseb A, Etzel CJ. et al. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog 2013; 52 (Suppl. 01) E139-E147
    CrossrefPubMedGoogle Scholar
  • 80 Bosch DE, Yeh MM. Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease. Hum Pathol 2017; 69: 55-62
    CrossrefPubMedGoogle Scholar
  • 81 Liu JZ, Hov JR, Folseraas T. et al; UK-PSCSC Consortium, International PSC Study Group, International IBD Genetics Consortium. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 2013; 45 (06) 670-675
    CrossrefPubMedGoogle Scholar
  • 82 Sabino J, Vieira-Silva S, Machiels K. et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut 2016; 65 (10) 1681-1689
    CrossrefPubMedGoogle Scholar
  • 83 Nobili V, Marcellini M, Devito R. et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006; 44 (02) 458-465
    CrossrefPubMedGoogle Scholar
  • 84 Younossi ZM, Stepanova M, Rafiq N. et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011; 53 (06) 1874-1882
    CrossrefPubMedGoogle Scholar
  • 85 Desmet VJ. Ductal plates in hepatic ductular reactions. Hypothesis and implications. I. Types of ductular reaction reconsidered. Virchows Arch 2011; 458 (03) 251-259
    CrossrefPubMedGoogle Scholar
  • 86 Richardson MM, Jonsson JR, Powell EE. et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 2007; 133 (01) 80-90
    CrossrefPubMedGoogle Scholar
  • 87 Farrell GC, Robertson GR, Leclercq I, Horsmans Y. Liver regeneration in obese mice with fatty livers: does the impairment have relevance for other types of fatty liver disease?. Hepatology 2002; 35 (03) 731-732
    CrossrefPubMedGoogle Scholar
  • 88 Leclercq IA, Field J, Farrell GC. Leptin-specific mechanisms for impaired liver regeneration in ob/ob mice after toxic injury. Gastroenterology 2003; 124 (05) 1451-1464
    CrossrefPubMedGoogle Scholar
  • 89 DeAngelis RA, Markiewski MM, Taub R, Lambris JD. A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-kappaB inhibitor, IkappaBalpha. Hepatology 2005; 42 (05) 1148-1157
    CrossrefPubMedGoogle Scholar
  • 90 Roskams T, Yang SQ, Koteish A. et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 2003; 163 (04) 1301-1311
    CrossrefPubMedGoogle Scholar
  • 91 Svegliati-Baroni G, Faraci G, Fabris L. et al. Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut 2011; 60 (01) 108-115
    CrossrefPubMedGoogle Scholar
  • 92 Gadd VL, Skoien R, Powell EE. et al. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology 2014; 59 (04) 1393-1405
    CrossrefPubMedGoogle Scholar
  • 93 Carotti S, Vespasiani-Gentilucci U, Perrone G, Picardi A, Morini S. Portal inflammation during NAFLD is frequent and associated with the early phases of putative hepatic progenitor cell activation. J Clin Pathol 2015; 68 (11) 883-890
    CrossrefPubMedGoogle Scholar
  • 94 Nobili V, Carpino G, Alisi A. et al. Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. Hepatology 2012; 56 (06) 2142-2153
    CrossrefPubMedGoogle Scholar
  • 95 Nobili V, Parkes J, Bottazzo G. et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009; 136 (01) 160-167
    CrossrefPubMedGoogle Scholar
  • 96 Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009; 2009: 831670
    CrossrefPubMedGoogle Scholar
  • 97 Miura K, Seki E, Ohnishi H, Brenner DA. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol Res Pract 2010; 2010: 362847
    CrossrefPubMedGoogle Scholar
  • 98 Brun P, Castagliuolo I, Di Leo V. et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007; 292 (02) G518-G525
    CrossrefPubMedGoogle Scholar
  • 99 Xu T, Du Y, Fang XB. et al. New insights into Nod-like receptors (NLRs) in liver diseases. Int J Physiol Pathophysiol Pharmacol 2018; 10 (01) 1-16
    PubMedGoogle Scholar
  • 100 Banales JM, Huebert RC, Karlsen T, Strazzabosco M, LaRusso NF, Gores GJ. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol 2019; 16 (05) 269-281
    CrossrefPubMedGoogle Scholar
  • 101 Haukeland JW, Damås JK, Konopski Z. et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006; 44 (06) 1167-1174
    CrossrefPubMedGoogle Scholar
  • 102 Hargrove L, Kennedy L, Demieville J. et al. Bile duct ligation-induced biliary hyperplasia, hepatic injury, and fibrosis are reduced in mast cell-deficient KitW-sh mice. Hepatology 2017; 65 (06) 1991-2004
    CrossrefPubMedGoogle Scholar
  • 103 Yang P, Wang Y, Tang W. et al. Western diet induces severe nonalcoholic steatohepatitis, ductular reaction, and hepatic fibrosis in liver CGI-58 knockout mice. Sci Rep 2020; 10 (01) 4701
    CrossrefPubMedGoogle Scholar
  • 104 Charlton M, Krishnan A, Viker K. et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011; 301 (05) G825-G834
    CrossrefPubMedGoogle Scholar
  • 105 Tandra S, Yeh MM, Brunt EM. et al. Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol 2011; 55 (03) 654-659
    CrossrefPubMedGoogle Scholar
  • 106 Hsu LC, Chang WC, Hiraoka L, Hsieh CL. Molecular cloning, genomic organization, and chromosomal localization of an additional human aldehyde dehydrogenase gene, ALDH6. Genomics 1994; 24 (02) 333-341
    CrossrefPubMedGoogle Scholar
  • 107 MacDonald GA, Bridle KR, Ward PJ. et al. Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3. J Gastroenterol Hepatol 2001; 16 (06) 599-606
    CrossrefPubMedGoogle Scholar
  • 108 Fromenty B, Berson A, Pessayre D. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. J Hepatol 1997; 26 (Suppl. 01) 13-22
    CrossrefPubMedGoogle Scholar
  • 109 Vega-Badillo J, Gutiérrez-Vidal R, Hernández-Pérez HA. et al. Hepatic miR-33a/miR-144 and their target gene ABCA1 are associated with steatohepatitis in morbidly obese subjects. Liver Int 2016; 36 (09) 1383-1391
    CrossrefPubMedGoogle Scholar
  • 110 Azzimato V, Jager J, Chen P. et al. Liver macrophages inhibit the endogenous antioxidant response in obesity-associated insulin resistance. Sci Transl Med 2020; 12 (532) eaaw9709
    CrossrefPubMedGoogle Scholar
  • 111 Lombardo J, Broadwater D, Collins R, Cebe K, Brady R, Harrison S. Hepatic mast cell concentration directly correlates to stage of fibrosis in NASH. Hum Pathol 2019; 86: 129-135
    CrossrefPubMedGoogle Scholar
  • 112 Segovia-Miranda F, Morales-Navarrete H, Kücken M. et al. Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression. Nat Med 2019; 25 (12) 1885-1893
    CrossrefPubMedGoogle Scholar
  • 113 Strazzabosco M, Fabris L. Development of the bile ducts: essentials for the clinical hepatologist. J Hepatol 2012; 56 (05) 1159-1170
    CrossrefPubMedGoogle Scholar
  • 114 Hirose Y, Itoh T, Miyajima A. Hedgehog signal activation coordinates proliferation and differentiation of fetal liver progenitor cells. Exp Cell Res 2009; 315 (15) 2648-2657
    CrossrefPubMedGoogle Scholar
  • 115 Syn WK, Jung Y, Omenetti A. et al. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009; 137 (04) 1478-1488.e8
    CrossrefPubMedGoogle Scholar
  • 116 Bruha R, Vitek L, Smid V. Osteopontin—a potential biomarker of advanced liver disease. Ann Hepatol 2020; 19 (04) 344-352
    CrossrefPubMedGoogle Scholar
  • 117 Syn WK, Choi SS, Liaskou E. et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011; 53 (01) 106-115
    CrossrefPubMedGoogle Scholar
  • 118 Kwon H, Song K, Han C. et al. Inhibition of hedgehog signaling ameliorates hepatic inflammation in mice with nonalcoholic fatty liver disease. Hepatology 2016; 63 (04) 1155-1169
    CrossrefPubMedGoogle Scholar
  • 119 Machado MV, Michelotti GA, Pereira TA. et al. Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease. J Hepatol 2015; 63 (04) 962-970
    CrossrefPubMedGoogle Scholar
  • 120 Chen P, Luo Q, Huang C. et al. Pathogenesis of non-alcoholic fatty liver disease mediated by YAP. Hepatol Int 2018; 12 (01) 26-36
    CrossrefPubMedGoogle Scholar
  • 121 Cadamuro M, Girardi N, Gores GJ, Strazzabosco M, Fabris L. The emerging role of macrophages in chronic cholangiopathies featuring biliary fibrosis: an attractive therapeutic target for orphan diseases. Front Med (Lausanne) 2020; 7: 115
    CrossrefPubMedGoogle Scholar
  • 122 Seki E, Park E, Fujimoto J. Toll-like receptor signaling in liver regeneration, fibrosis and carcinogenesis. Hepatol Res 2011; 41 (07) 597-610
    CrossrefPubMedGoogle Scholar
  • 123 Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20 (23) 7381-7391
    CrossrefPubMedGoogle Scholar
  • 124 Kiziltas S. Toll-like receptors in pathophysiology of liver diseases. World J Hepatol 2016; 8 (32) 1354-1369
    CrossrefPubMedGoogle Scholar
  • 125 Farrell GC, Haczeyni F, Chitturi S. Pathogenesis of NASH: how metabolic complications of overnutrition favour lipotoxicity and pro-inflammatory fatty liver disease. Adv Exp Med Biol 2018; 1061: 19-44
    CrossrefPubMedGoogle Scholar
  • 126 Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 2018; 53 (03) 362-376
    CrossrefPubMedGoogle Scholar
  • 127 Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci 2019; 76 (01) 99-128
    CrossrefPubMedGoogle Scholar
  • 128 Li Z, Lian Y, Wei R. et al. Effects of taraxasterol against ethanol and high-fat diet-induced liver injury by regulating TLR4/MyD88/NF-κB and Nrf2/HO-1 signaling pathways. Life Sci 2020; 262: 118546
    CrossrefPubMedGoogle Scholar
  • 129 Vespasiani-Gentilucci U, Carotti S, Perrone G. et al. Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD. Liver Int 2015; 35 (02) 569-581
    CrossrefPubMedGoogle Scholar
  • 130 Ge X, Wang L, Li M. et al. Vitamin D/VDR signaling inhibits LPS-induced IFNγ and IL-1β in Oral epithelia by regulating hypoxia-inducible factor-1α signaling pathway. Cell Commun Signal 2019; 17 (01) 18
    CrossrefPubMedGoogle Scholar
  • 131 Xia Y, Zhao G, Lin J. et al. 1,25(OH)2D3 and VDR signaling pathways regulate the inhibition of dectin-1 caused by cyclosporine A in response to aspergillus fumigatus in human corneal epithelial cells. PLoS One 2016; 11 (10) e0164717
    CrossrefPubMedGoogle Scholar
  • 132 Wang H, Zhang Q, Chai Y. et al. 1,25(OH)2D3 downregulates the toll-like receptor 4-mediated inflammatory pathway and ameliorates liver injury in diabetic rats. J Endocrinol Invest 2015; 38 (10) 1083-1091
    CrossrefPubMedGoogle Scholar
  • 133 Borges-Canha M, Neves JS, Mendonça F. et al. The impact of vitamin D in non-alcoholic fatty liver disease: a cross-sectional study in patients with morbid obesity. Diabetes Metab Syndr Obes 2021; 14: 487-495
    CrossrefPubMedGoogle Scholar
  • 134 Barchetta I, Carotti S, Labbadia G. et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology 2012; 56 (06) 2180-2187
    CrossrefPubMedGoogle Scholar
  • 135 Yu L, Li Y, Grisé A, Wang H. CGI-58: versatile regulator of intracellular lipid droplet homeostasis. Adv Exp Med Biol 2020; 1276: 197-222
    CrossrefPubMedGoogle Scholar
  • 136 Youssefian L, Vahidnezhad H, Saeidian AH. et al. Inherited non-alcoholic fatty liver disease and dyslipidemia due to monoallelic ABHD5 mutations. J Hepatol 2019; 71 (02) 366-370
    CrossrefPubMedGoogle Scholar
  • 137 Povero D, Feldstein AE. Novel molecular mechanisms in the development of non-alcoholic steatohepatitis. Diabetes Metab J 2016; 40 (01) 1-11
    CrossrefPubMedGoogle Scholar
  • 138 Lefere S, Van de Velde F, Hoorens A. et al. Angiopoietin-2 promotes pathological angiogenesis and is a therapeutic target in murine nonalcoholic fatty liver disease. Hepatology 2019; 69 (03) 1087-1104
    CrossrefPubMedGoogle Scholar
  • 139 Lei L, Ei Mourabit H, Housset C, Cadoret A, Lemoinne S. Role of angiogenesis in the pathogenesis of NAFLD. J Clin Med 2021; 10 (07) 1338
    CrossrefPubMedGoogle Scholar
  • 140 Mariotti V, Fiorotto R, Cadamuro M, Fabris L, Strazzabosco M. New insights on the role of vascular endothelial growth factor in biliary pathophysiology. JHEP Rep 2021; 3 (03) 100251
    CrossrefPubMedGoogle Scholar
  • 141 Siddiqui H, Rawal P, Bihari C, Arora N, Kaur S. Vascular endothelial growth factor promotes proliferation of epithelial cell adhesion molecule-positive cells in nonalcoholic steatohepatitis. J Clin Exp Hepatol 2020; 10 (04) 275-283
    CrossrefPubMedGoogle Scholar
  • 142 Saeed WK, Jun DW, Jang K, Koh DH. Necroptosis signaling in liver diseases: an update. Pharmacol Res 2019; 148: 104439
    CrossrefPubMedGoogle Scholar
  • 143 Afonso MB, Rodrigues PM, Carvalho T. et al. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis. Clin Sci (Lond) 2015; 129 (08) 721-739
    CrossrefPubMedGoogle Scholar
  • 144 Afonso MB, Castro RE, Rodrigues CMP. Processes exacerbating apoptosis in non-alcoholic steatohepatitis. Clin Sci (Lond) 2019; 133 (22) 2245-2264
    CrossrefPubMedGoogle Scholar
  • 145 Gautheron J, Vucur M, Reisinger F. et al. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol Med 2014; 6 (08) 1062-1074
    CrossrefPubMedGoogle Scholar
  • 146 Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol 2020; 72 (01) 95-103
    CrossrefPubMedGoogle Scholar